Search
Search Results
-
Rottlerin and genistein inhibit neuroblastoma cell proliferation and invasion through EF2K suppression and related protein pathways
Neuroblastoma is one of the most common solid tumors in children younger than 1 year of age, with poor prognosis and survival rates. Therefore, novel...
-
From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models
BackgroundNeuroblastoma (NB) represents the most frequent and aggressive form of extracranial solid tumor of infants. Although the overall survival...
-
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
Vα24-invariant natural killer T (NKT) cells have shown potent anti-tumor properties in murine tumor models and have been linked to favorable outcomes...
-
Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models
BackgroundThe majority of high-risk neuroblastomas harbor telomerase activity, and telomerase-interacting compounds, such as 6-thio-2’-deoxyguanosine...
-
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
BackgroundDevelopment of resistance to targeted therapies has tempered initial optimism that precision oncology would improve poor outcomes for...
-
Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program
BackgroundEpigenetic programming during development is essential for determining cell lineages, and alterations in this programming contribute to the...
-
The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis
ObjectiveNeuroblastoma is a common extracranial solid tumor of childhood. Recently, multiple treatments have been practiced including...
-
Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway
The “undruggable” MYC oncoproteins are deregulated in 70% human cancers. The approval of DFMO, an irreversible inhibitor of ornithine oxidase (ODC1)...
-
KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m6A reader YTHDC1 protein degradation
BackgroundNeuroblastoma (NB) patients with amplified MYCN often face a grim prognosis and are resistant to existing therapies, yet MYCN protein is...
-
Risk of develo** second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database
BackgroundNeuroblastoma is a common extracranial malignant tumor in children. Its main treatment modality is a combination of chemotherapy,...
-
Recent advances in the developmental origin of neuroblastoma: an overview
Neuroblastoma (NB) is a pediatric tumor that originates from neural crest-derived cells undergoing a defective differentiation due to genomic and...
-
BPTF in bone marrow provides a potential progression biomarker regulated by TFAP4 through the PI3K/AKT pathway in neuroblastoma
BackgroundNeuroblastoma (NB) is the most common extracranial malignant solid tumor in children, which is highly prone to bone marrow (BM) metastasis....
-
A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma
Neuroblastoma is the most common extra-cranial solid tumor in children, representing approximately 8% of all malignant childhood tumors and 15% of...
-
Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma
BackgroundMinimal residual disease (MRD) measurement is a cornerstone of contemporary acute lymphoblastic leukaemia (ALL) treatment. The presence of...
-
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
BackgroundHigh-risk neuroblastoma patients have a 5-year survival rate of less than 50%. It’s an urgent need to identify new therapeutic targets and...
-
FGFR1 is a potential therapeutic target in neuroblastoma
BackgroundFGFR1 regulates cell–cell adhesion and extracellular matrix architecture and acts as oncogene in several cancers. Potential cancer driver...
-
MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma
BackgroundMinichromosome maintenance complex component 6 (MCM6), as an important replication permission factor, is involved in the pathogenesis of...
-
A signature based on five immune-related genes to predict the survival and immune characteristics of neuroblastoma
BackgroundMYCN amplification (MNA) has been proved to be related to poor prognosis in neuroblastoma (NBL), but the MYCN-related immune signatures and...
-
Inhibition of glycolysis and mitochondrial respiration promotes radiosensitisation of neuroblastoma and glioma cells
BackgroundNeuroblastoma accounts for 7% of paediatric malignancies but is responsible for 15% of all childhood cancer deaths. Despite rigorous...
